Top Health Tech Companies With Best Stability & Growth (10,000+)

Strong Revenue Growth: Reports indicate Artera reached $100M in contracted ARR by end of 2025, with external growth lists (e.g., Inc. 5000, Deloitte Fast 500) reflecting multi‑year expansion. Third‑party coverage echoed the funding round and revenue milestone as of December 2025.

Investor Backing & Capital Strength: Artera secured a $65M growth investment in December 2025 led by Lead Edge Capital with participation from existing investors, positioned to accelerate expansion and adoption of its platform. The financing was framed explicitly as growth capital rather than restructuring.

Market Expansion: FedRAMP Class D (High) authorization for Harmony Federal Edition in June 2026 enables deeper work with federal agencies such as the VA, DoD, and IHS, typically a catalyst for federal growth. Additional signals include EHR-channel distribution (e.g., MEDITECH) and recognition that can aid enterprise penetration.

Profitability: Results show adjusted operating income and EPS rising across recent periods, and guidance indicates continued profit expansion. Management actions, including maintaining a higher earnings outlook, point to durable margin performance despite mix and cost headwinds.

Future-Ready Strategy: The company is refocusing on core distribution, divesting non-core units, and committing significant investments to expand U.S. network capacity and resilience. Acquisitions in specialty care, new high-value distribution agreements, and digital platform upgrades support long-term growth.

Strong Market Position & Advantage: Scale as one of the Big Three distributors and Fortune 10 standing underpin resilience in a concentrated market. Specialty logistics and global capabilities differentiate the platform in complex, higher-growth categories.

Profitability: The company reports achieving annual profitability in 2023 and sustaining it, with a 2025 Rule‑of‑40 score of 51% indicating efficiency in combining growth and margin. These signals point to durable unit economics rather than growth fueled by losses.

Strong Revenue Growth: Leadership cites roughly a 30% revenue CAGR over the past three years with acceleration into 2026. Continued national marketing and expanded booking channels align with ongoing top‑line momentum.

Strategic Partnerships: New integrations—such as Blue Shield of California’s member scheduling and Yelp’s real‑time booking—extend distribution beyond the core marketplace. These moves position the platform as access infrastructure across payer and high‑intent consumer surfaces.

Strong Market Position & Advantage: Public materials consistently cite more than 1,300 organizations on the platform, including global pharmas like Merck, Moderna, and Sanofi. This breadth and logo depth indicate entrenched presence across modern biotech R&D.

Innovation-Driven Growth: The company continues launching new capabilities (e.g., Benchling Models, Biologics updates, Validated Cloud) and reports broad uptake of Benchling AI after GA, suggesting expanding use cases across its base. Ecosystem moves like one‑click ordering integrations point to product‑led expansion.

Strong Revenue Growth: Independent estimates describe ARR above $200M in 2024 and increasing year over year. This supports a view of continued top‑line expansion despite a tougher market context.

Strong Revenue Growth: Revenue is accelerating with consistent year-over-year gains and guidance pointing to continued expansion through 2026. Record platform activity and rising deal momentum reinforce top-line trajectory.

Customer Loyalty & Retention: Net dollar retention has improved alongside growth in core genomics customers, indicating expanding usage among existing accounts. Record analyses and repeat adoption across cohorts suggest durable engagement.

Market Expansion: Expansion in the U.S. and APAC and the addition of large integrated health systems support a broader geographic and enterprise footprint. Increasing uptake of newer applications strengthens presence across regions.

Market Expansion: Public claims and profiles trace clinic adoption from a 2019 baseline to “over 23,000” hospitals/clinics by 2024–2026, indicating sustained footprint growth. Additional signals such as active manufacturer program pages and continued rollouts for groups suggest deeper reach across segments.

Product Line Growth: The platform has expanded beyond procurement into Home Delivery pharmacy and added integrations with major practice‑management systems, embedding it further into daily workflows. Ongoing feature launches for groups and hospitals are cited as leading indicators of broader adoption.

Strategic Partnerships: Company and partner pages reference collaborations like AVMA Direct Connect and active manufacturer programs (e.g., Dechra), signaling vendor‑side engagement. Ecosystem integrations and partner endorsements depict a well‑connected position in the animal health supply chain.

Strong Revenue Growth: Public materials indicate revenue remained at $1B+ in FY2024 after first crossing the milestone in 2023, suggesting ongoing scale and momentum.

Strong Hiring & Retention: Labor‑market analytics estimate headcount rose into 2025, a common proxy for expansion at private software firms.

Strong Market Position & Advantage: Multiple 2026 Best in KLAS awards and active launches/events in 2025–2026 (e.g., IntelliCare/RCM, HIMSS26) indicate competitive traction and pipeline‑building.

Investor Backing & Capital Strength: Recent financing includes an $80M Series C in April 2026, bringing total funding above $160M and implying a valuation near $955M. Feedback suggests this capital is earmarked to expand AI capabilities and go‑to‑market, reinforcing runway and scale.

Strong Market Position & Advantage: The company reports supporting 16 of the top 20 MedTech companies and crossing the 300‑customer mark by 2025, indicating deep enterprise penetration. Hundreds of MedTech organizations and large identified pipeline point to solid positioning within its niche.

Innovation-Driven Growth: Ongoing platform expansion includes AI features launched in 2025 and expanded “agentic AI” tied to the 2026 raise. This cadence indicates active investment in R&D and commercial enablement.

Strong Market Position & Advantage: Long-running Best in KLAS recognition for Business Decision Support, including a publicly documented 2024 award, signals durable category leadership. Feedback suggests this leadership correlates with stable renewals and upsells.

Product Line Growth: Recent launches such as AI-driven Predictive Analytics (March 31, 2026) and StrataSignal AI in 2025 indicate ongoing R&D and platform investment. Feedback suggests a steady cadence of enhancements supports expansion within existing accounts.

Investor Backing & Capital Strength: Placement within Roper Technologies’ Application Software portfolio, with segment commentary noting sustained organic growth and the EPSi bolt-on, provides financial stability and scale. Feedback suggests parent-level resources support continued investment and inorganic expansion.

Investor Backing & Capital Strength: Company announcements highlight a $25M Series B at a significant valuation step-up with reputable investors participating. This indicates strong access to growth capital to fund scaling efforts.

Market Expansion: Company materials cite 10,000+ agents using the platform and roughly 225,000–250,000 enrollments in 2025, alongside notable gains at partner agencies. Active hiring and increases in RTS agent counts further signal expanding commercial reach.

Innovation-Driven Growth: Spark positions itself as an all-in-one, Medicare-specific platform with in-house software, AI features, and operational tooling for agencies and call centers. Leadership additions (CTO and COO) point to continued product and operating-model build-out.

Investor Backing & Capital Strength: Public reports indicate a sizable October 2025 Series A in the $31–38M range with coverage from industry outlets, signaling meaningful investor confidence and runway for scaling. Feedback suggests this capital is aimed at expanding the network and platform capabilities.

Market Expansion: Company materials describe a nationwide footprint of 4,800+ imaging partners and integrations that extended access to roughly two million people over 18 months, indicating rapid geographic and member reach growth. Trade coverage and ongoing hiring activity into 2026 are directionally consistent with scaling operations.

Strategic Partnerships: Evidence points to employer and health-plan integrations and ecosystem mentions (e.g., Carrum Health), reinforcing credibility in the employer-benefits channel. References to multiple Fortune 100 customers further suggest enterprise traction.

Investor Backing & Capital Strength: Investor backing from a $30M Series A in March 2022 led by Optum Ventures with participation from Cigna Ventures provides runway for a small team. Signals suggest this capital supports measured execution in the absence of newer disclosed rounds.

Product Line Growth: Ongoing product/content updates in 2026 and prior launch of Flume Relay indicate active development of the healthcare iPaaS offering. Recent case‑style posts and refreshed documentation point to continued platform maturation.

Future-Ready Strategy: The October 2023 divestiture of TPA operations to focus on a payer data/integration platform concentrates resources on scalable software. Positioning around canonical data models, interoperability (EDI/FHIR), and automation aligns with evolving payer needs.

Investor Backing & Capital Strength: Funding progressed from a Series A to a Series B and a Series C led by well-known investors, with mainstream and trade press coverage indicating strong capital access and runway.

Strategic Partnerships: Broad integrations with leading senior‑living EHRs and a named Client Advisory Board from recognized operators indicate deep ecosystem alignment and industry engagement.

Market Expansion: Portfolio‑level rollouts and added integrations that open access across much of the senior‑living ecosystem suggest an expanding commercial footprint.

Investor Backing & Capital Strength: Back-to-back late-stage funding rounds in 2026 with a significant valuation step-up indicate strong access to capital and investor conviction. Participation from well-known venture and strategic investors underscores financing momentum.

Strong Revenue Growth: Company disclosures around the 2026 raises cite rapid year-over-year revenue gains and a growing recurring revenue base. The pace is described as compounding across multiple years.

Market Expansion: Public announcements reference service to millions of members across hundreds of organizations and recent agreements with health systems and plans. These signals point to a widening commercial footprint for an employer-focused private company.

Investor Backing & Capital Strength: A $300 million growth investment from Vista Equity Partners in January 2022 is cited as providing resources to scale products and go‑to‑market. This capital support aligns with subsequent product launches and acquisitions through 2026.

Product Line Growth: New offerings such as the AI‑powered Operator Console (February 2026) and acquisitions of Twiage (November 2024) and eVideon (August 2025) expand the platform from EMS intake to inpatient smart‑room and operator workflows. These moves extend TigerConnect beyond messaging into broader clinical and patient engagement workflows.

Strong Market Position & Advantage: Recognition as a Leader in G2’s 2024–2025 reports, continued Leader placement in Gartner’s 2025 CC&C Magic Quadrant, and strong KLAS 2025 signals indicate durable category standing. Company materials also showcase large U.S. health system logos and ongoing momentum claims.

Investor Backing & Capital Strength: Feedback suggests recent seed rounds (e.g., Seed III in early 2023) and participation in reputable accelerators signal ongoing access to capital and investor confidence.

Market Expansion: Feedback suggests multi‑state operations, active partner recruitment, and rollouts with health systems indicate geographic and network growth through 2025–2026.

Innovation-Driven Growth: Feedback suggests SOC 2 Type I, a granted patent, and a TAG Top 10 Innovative Company recognition point to product maturation and innovation supporting scale-up.

Innovation-Driven Growth: Public materials cite 5–7 FDA-cleared algorithms, 20+ issued patents, and 4M+ hours of on-body data, plus a December 2025 FDA clearance for the eVO2peak module. The acquisition of physIQ further deepened digital biomarker capabilities and analytics.

Market Expansion: The company reports deployment across 22+ to 26+ countries and states plans to expand access into Europe and Asia by 2026. Integration into Kardigan’s platform is framed as extending reach to more patients and providers.

Strong Hiring & Retention: Hiring posture appears active with a dedicated careers page, multiple open roles on job hubs, and a listed 51–200 (≈80+) employee footprint. LinkedIn activity and recent hiring posts suggest ongoing team growth since early 2025.

Strong Revenue Growth: Reported revenue increased sharply in 2025 and continued to rise in Q1 2026, with management raising full‑year 2026 revenue guidance and signaling improved operating leverage.

Diversified Revenue Streams: Both Diagnostics and the higher‑margin Data & Applications businesses showed growth in recent updates, indicating multiple engines driving the top line.

Strategic Partnerships: The company expanded multi‑year collaborations with major pharmaceutical firms and highlighted a sizable pipeline and contract values that support future demand.

Strong Market Position & Advantage: Public materials indicate a nationwide footprint across roughly 30,000 physicians’ offices serving about 125,000 providers, with expanded MRC accreditation across waiting, exam and back‑office screens signaling a measurable, scaled network. These indicators suggest durable competitive positioning at the point of care.

Product Line Growth: In March 2026 the company launched a Consumer Health Network and added programmatic access via PatientPoint Health Audiences. These offerings expand monetization routes and modernize buying options for brands.

Investor Backing & Capital Strength: Advent International signed a definitive agreement to acquire the company to accelerate network growth and product innovation. Earlier private capital injections and active partnerships further suggest access to resources to fund expansion.

Strong Revenue Growth: Independent market research estimates indicate annualized revenue roughly doubled in 2024, pointing to rapid topline expansion into 2025. This trajectory aligns with other scale markers like cumulative sessions growth.

Market Expansion: Company materials describe nationwide therapy and psychiatry availability and 10M+ cumulative sessions by mid‑2026, indicating expanding reach and utilization. Press mentions of 21,000+ licensed providers with next‑day access further underscore capacity growth.

Strategic Partnerships: Recent references to integrations with major insurers and health‑system/employer channels (e.g., Kaiser regions, Stanford Health Care Alliance, Amazon programs) suggest deepening distribution. Active hiring for partnership roles and multiple plan collaborations reinforce go‑to‑market scaling.